CompletedNCT02418819

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Medication studyAges 18–45United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Listed locations: Arcadia and 5 more locationsSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateStarted: April 2015

Recruitment status: Completed
Enrollment listed in the registry: 103
Sponsor: Pfizer
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug, OTHER
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 45 Years
Official registry ID: NCT02418819
Official title: Show the full official title
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, SPONSOR OPEN, PHASE 1B STUDY TO EXAMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-06412562 IN PSYCHIATRICALLY STABLE SUBJECTS WITH SCHIZOPHRENIA

Completed

Arcadia · Glendale · Baltimore

2 more locations

FAQ

Who is behind this study?

The study sponsor is Pfizer.

Did this study involve medication?

Yes. The study involved medication, including PF-06412562 3mg BID, PF-06412562 9mg BID and PF-06412562 45mg BID.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.